Poterior ubtenon triamcinolone acetonide for refractory diabetic macular edema

Purpoe To evaluate poterior ubtenon injection of triamcinolone acetonide for refractory diabetic macular edema (DME). Deign Retropective, interventional, cae erie. Method etting: Clinical practice. patient population: Patient with peritent clinically ignificant DME involving the center of the fovea 3 or more month after one or more treatment of focal macular photocoagulation were included. Excluion criteria were a hitory of corticoteroid-reponive intraocular preure (IOP) rie, intraocular urgery within 3 month, and any laer treatment within 1 month. procedure: All patient received an ophthalmic hitory and examination including bet-corrected nellen viual acuity, IOP meaurement, anterior egment examination including evaluation of len tatu with LOC II criteria, dilated fundu examination, and a poterior ubtenon injection of 40 mg triamcinolone acetonide at baeline. Patient were reevaluated at 1, 3, 6, and 12 month after injection. Reult eventy-three injection were performed in 63 eye of 50 patient. The mean baeline viual acuity wa 20/80. Mean viual acuity ignificantly improved to 20/50 at 1 month, then tabilized to 20/65 at 3 month, 20/68 at 6 month, and 20/63 at 12 month. Complication were rare, with a tranient ignificant rie in intraocular preure at the 3-month evaluation and ptoi in two patient. Concluion Viual acuitie remained table or improved over a 12-month period after poterior ubtenon triamcinolone injection for refractory DME. There wa a tatitically ignificant improvement in viual acuity at 1 month.